UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY

Home

Download

Statistics

Examples

Help

Contact

level1

	Fusion Gene Summary
	Fusion Gene Sample Information
	Fusion ORF Analysis
	Fusion Amino Acid Sequences
	Fusion Protein Functional Features
	Fusion Protein-Protein Interaction
	Related drugs with this fusion protein
	Related disease with this fusion protein

Fusion Protein:PTPN14-MARK3

Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PTPN14-MARK3
	FusionPDB ID: 70219
	FusionGDB2.0 ID: 70219
		Hgene	Tgene
	Gene symbol	PTPN14	MARK3
	Gene ID	5784	4140
	Gene name	protein tyrosine phosphatase non-receptor type 14	microtubule affinity regulating kinase 3
	Synonyms	CATLPH\|PEZ\|PTP36	CTAK1\|KP78\|PAR1A\|Par-1a\|VIPB
	Cytomap	1q32.3-q41	14q32.32-q32.33
	Type of gene	protein-coding	protein-coding
	Description	tyrosine-protein phosphatase non-receptor type 14cytoskeletal-associated protein tyrosine phosphataseprotein-tyrosine phosphatase pez	MAP/microtubule affinity-regulating kinase 3C-TAK1ELKL motif kinase 2EMK-2cdc25C-associated protein kinase 1protein kinase STK10ser/Thr protein kinase PAR-1serine/threonine-protein kinase p78
	Modification date	20200313	20200313
	UniProtAcc	.	P27448
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000366956, ENST00000543945, ENST00000491277,	ENST00000561071, ENST00000216288, ENST00000303622, ENST00000335102, ENST00000416682, ENST00000429436, ENST00000440884, ENST00000553942,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	9 X 11 X 5=495	16 X 19 X 9=2736
	# samples	11	21
	** MAII score	log2(11/495*10)=-2.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(21/2736*10)=-3.70360699721978 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context (manual curation of fusion genes in FusionPDB)	PubMed: PTPN14 [Title/Abstract] AND MARK3 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PTPN14(214637972)-MARK3(103928741), # samples:1
Anticipated loss of major functional domain due to fusion event.	PTPN14-MARK3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PTPN14-MARK3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PTPN14-MARK3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PTPN14-MARK3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PTPN14-MARK3 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. PTPN14-MARK3 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. PTPN14-MARK3 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. PTPN14-MARK3 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	PTPN14	GO:0046825	regulation of protein export from nucleus	22948661
Tgene	MARK3	GO:0018105	peptidyl-serine phosphorylation	9543386
Tgene	MARK3	GO:0032092	positive regulation of protein binding	9543386
Tgene	MARK3	GO:0035331	negative regulation of hippo signaling	28087714
Tgene	MARK3	GO:0036289	peptidyl-serine autophosphorylation	9543386

Fusion gene breakpoints across PTPN14 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across MARK3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Gene Sample Information

Fusion gene information from FusionGDB2.0.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	OV	TCGA-24-2297	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+

Top

Fusion ORF Analysis

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000543945	PTPN14	chr1	214637972	-	ENST00000440884	MARK3	chr14	103928741	+	1696	174	0	1670	556
ENST00000543945	PTPN14	chr1	214637972	-	ENST00000416682	MARK3	chr14	103928741	+	2014	174	0	1880	626
ENST00000543945	PTPN14	chr1	214637972	-	ENST00000429436	MARK3	chr14	103928741	+	2552	174	0	1952	650
ENST00000543945	PTPN14	chr1	214637972	-	ENST00000303622	MARK3	chr14	103928741	+	2485	174	0	1880	626
ENST00000543945	PTPN14	chr1	214637972	-	ENST00000216288	MARK3	chr14	103928741	+	2432	174	0	1832	610
ENST00000543945	PTPN14	chr1	214637972	-	ENST00000553942	MARK3	chr14	103928741	+	1944	174	0	1925	641
ENST00000543945	PTPN14	chr1	214637972	-	ENST00000335102	MARK3	chr14	103928741	+	1953	174	0	1952	650

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000543945	ENST00000440884	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+	0.004527659	0.9954724
ENST00000543945	ENST00000416682	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+	0.007230932	0.9927691
ENST00000543945	ENST00000429436	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+	0.002687376	0.9973126
ENST00000543945	ENST00000303622	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+	0.002588115	0.9974119
ENST00000543945	ENST00000216288	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+	0.002722023	0.99727803
ENST00000543945	ENST00000553942	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+	0.009804621	0.99019533
ENST00000543945	ENST00000335102	PTPN14	chr1	214637972	-	MARK3	chr14	103928741	+	0.009097172	0.99090284

Top

Fusion Amino Acid Sequences

For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

>70219_70219_1_PTPN14-MARK3_PTPN14_chr1_214637972_ENST00000543945_MARK3_chr14_103928741_ENST00000216288_length(amino acids)=610AA_BP=58
MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELREIVSAVQYCHQKRIVHRDLKAENLLLDADMNIK
IADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENL
LKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSEVRP
SSDLNNSTGQSPHHKVQRSVFSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGKGIAPASPMLGNASNPN
KADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRIRFPRGTASRSTFHGQP
RERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRSRNVSAEQKDENKEAKPRSLRFTWSMKTTSSMDPGDMMREIRKVL

--------------------------------------------------------------

>70219_70219_2_PTPN14-MARK3_PTPN14_chr1_214637972_ENST00000543945_MARK3_chr14_103928741_ENST00000303622_length(amino acids)=626AA_BP=58
MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELREIVSAVQYCHQKRIVHRDLKAENLLLDADMNIK
IADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENL
LKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDA
SDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVFSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGK
GIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRI
RFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRSRNVSAEQKDENKEAKPRSLRFTWSMKTT

--------------------------------------------------------------

>70219_70219_3_PTPN14-MARK3_PTPN14_chr1_214637972_ENST00000543945_MARK3_chr14_103928741_ENST00000335102_length(amino acids)=650AA_BP=58
MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELREIVSAVQYCHQKRIVHRDLKAENLLLDADMNIK
IADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENL
LKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDA
SDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVFSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGK
GIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRI
RFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRRNMSFRFIKRLPTEYERNGRYEGSSRNVS
AEQKDENKEAKPRSLRFTWSMKTTSSMDPGDMMREIRKVLDANNCDYEQRERFLLFCVHGDGHAENLVQWEMEVCKLPRLSLNGVRFKRI

--------------------------------------------------------------

>70219_70219_4_PTPN14-MARK3_PTPN14_chr1_214637972_ENST00000543945_MARK3_chr14_103928741_ENST00000416682_length(amino acids)=626AA_BP=58
MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELREIVSAVQYCHQKRIVHRDLKAENLLLDADMNIK
IADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENL
LKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDA
SDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVFSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGK
GIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRI
RFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRSRNVSAEQKDENKEAKPRSLRFTWSMKTT

--------------------------------------------------------------

>70219_70219_5_PTPN14-MARK3_PTPN14_chr1_214637972_ENST00000543945_MARK3_chr14_103928741_ENST00000429436_length(amino acids)=650AA_BP=58
MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELREIVSAVQYCHQKRIVHRDLKAENLLLDADMNIK
IADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENL
LKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDA
SDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVFSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGK
GIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRI
RFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRRNMSFRFIKRLPTEYERNGRYEGSSRNVS
AEQKDENKEAKPRSLRFTWSMKTTSSMDPGDMMREIRKVLDANNCDYEQRERFLLFCVHGDGHAENLVQWEMEVCKLPRLSLNGVRFKRI

--------------------------------------------------------------

>70219_70219_6_PTPN14-MARK3_PTPN14_chr1_214637972_ENST00000543945_MARK3_chr14_103928741_ENST00000440884_length(amino acids)=556AA_BP=58
MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELREIVSAVQYCHQKRIVHRDLKELRERVLRGKYRI
PFYMSTDCENLLKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYL
LLGRKSSELDASDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVFSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISS
RKSSGSAVGGKGIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTH
SISSAATPDRIRFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRRNMSFRFIKSRNVSAEQK
DENKEAKPRSLRFTWSMKTTSSMDPGDMMREIRKVLDANNCDYEQRERFLLFCVHGDGHAENLVQWEMEVCKLPRLSLNGVRFKRISGTS

--------------------------------------------------------------

>70219_70219_7_PTPN14-MARK3_PTPN14_chr1_214637972_ENST00000543945_MARK3_chr14_103928741_ENST00000553942_length(amino acids)=641AA_BP=58
MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELREIVSAVQYCHQKRIVHRDLKAENLLLDADMNIK
IADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENL
LKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDA
SDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVFSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGK
GIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRI
RFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRRLPTEYERNGRYEGSSRNVSAEQKDENKE
AKPRSLRFTWSMKTTSSMDPGDMMREIRKVLDANNCDYEQRERFLLFCVHGDGHAENLVQWEMEVCKLPRLSLNGVRFKRISGTSIAFKN

--------------------------------------------------------------

Top

Fusion Protein Functional Features

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:214637972/chr14:103928741)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
.	MARK3 P27448
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.	FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:23666762). Phosphorylates CDC25C on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus (PubMed:16980613). Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1 (PubMed:28087714). {ECO:0000269\|PubMed:16980613, ECO:0000269\|PubMed:23666762, ECO:0000269\|PubMed:28087714}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page
* Minus value of BPloci means that the break pointn is located before the CDS.

- Retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000216288

326_365

161.0

714.0

Domain

UBA

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000216288

704_753

161.0

714.0

Domain

KA1

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000303622

326_365

161.0

730.0

Domain

UBA

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000303622

704_753

161.0

730.0

Domain

KA1

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000416682

326_365

184.0

753.0

Domain

UBA

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000416682

704_753

184.0

753.0

Domain

KA1

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000429436

326_365

161.0

754.0

Domain

UBA

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000429436

704_753

161.0

754.0

Domain

KA1

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000440884

326_365

161.0

660.0

Domain

UBA

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000440884

704_753

161.0

660.0

Domain

KA1

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000553942

326_365

161.0

745.0

Domain

UBA

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000553942

704_753

161.0

745.0

Domain

KA1

- Not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

PTPN14

chr1:214637972

chr14:103928741

ENST00000366956

566_573

58.0

1188.0

Compositional bias

Note=Poly-Pro

Hgene

PTPN14

chr1:214637972

chr14:103928741

ENST00000366956

709_716

58.0

1188.0

Compositional bias

Note=Poly-Glu

Hgene

PTPN14

chr1:214637972

chr14:103928741

ENST00000366956

21_306

58.0

1188.0

Domain

FERM

Hgene

PTPN14

chr1:214637972

chr14:103928741

ENST00000366956

909_1180

58.0

1188.0

Domain

Tyrosine-protein phosphatase

Hgene

PTPN14

chr1:214637972

chr14:103928741

ENST00000366956

1121_1127

58.0

1188.0

Region

Substrate binding

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000216288

56_307

161.0

714.0

Domain

Protein kinase

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000303622

56_307

161.0

730.0

Domain

Protein kinase

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000416682

56_307

184.0

753.0

Domain

Protein kinase

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000429436

56_307

161.0

754.0

Domain

Protein kinase

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000440884

56_307

161.0

660.0

Domain

Protein kinase

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000553942

56_307

161.0

745.0

Domain

Protein kinase

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000216288

62_70

161.0

714.0

Nucleotide binding

ATP

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000303622

62_70

161.0

730.0

Nucleotide binding

ATP

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000416682

62_70

184.0

753.0

Nucleotide binding

ATP

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000429436

62_70

161.0

754.0

Nucleotide binding

ATP

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000440884

62_70

161.0

660.0

Nucleotide binding

ATP

Tgene

MARK3

chr1:214637972

chr14:103928741

ENST00000553942

62_70

161.0

745.0

Nucleotide binding

ATP

Top

Fusion Protein-Protein Interaction

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160)

Gene

PPI interactors

Protein-protein interactors based on sequence similarity (STRING)

Gene	STRING network
PTPN14
MARK3

- Retained interactions in fusion protein (protein functional feature from UniProt).

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost interactions due to fusion (protein functional feature from UniProt).

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs to PTPN14-MARK3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PTPN14-MARK3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source